Alaunos Therapeutics (TCRT) Share-based Compensation (2009 - 2026)
Alaunos Therapeutics (TCRT) reported Share-based Compensation of $56000.0 for Q1 2026, down 17.65% on a YoY basis from $68000.0 in Q1 2025, and down 76.95% quarter-over-quarter from $243000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Share-based Compensation (2009 - 2026) Analysis & Trends
Alaunos Therapeutics has reported Share-based Compensation for 18 years, with the latest figure at $56000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 17.65% year-over-year to $56000.0; the trailing twelve-month figure through Mar 2026 stood at $784000.0 (up 137.58% YoY), and the FY2025 full-year result was $796000.0, up 82.99% from the prior year.
- Share-based Compensation for Q1 2026 stood at $56000.0, down from $243000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $990000.0 in Q2 2022, with the low at $56000.0 in Q1 2026.
- Historically, Share-based Compensation has averaged $447882.4 across 5 years, with a median of $250000.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 88.98% — and 2025, when it jumped 276.25%.
- Alaunos Therapeutics' Share-based Compensation stood at $877000.0 in 2022, then slumped by 71.49% to $250000.0 in 2023, then plunged by 67.6% to $81000.0 in 2024, then surged by 200.0% to $243000.0 in 2025, then slumped by 76.95% to $56000.0 in 2026.
- The last three Share-based Compensation figures came in at $56000.0 (Q1 2026), $243000.0 (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 243,000.00 |
| Dec 31, 2025 | 243,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Mar 31, 2024 | 172,000.00 |
| Mar 31, 2024 | 172,000.00 |
| Dec 31, 2023 | 250,000.00 |
| Dec 31, 2023 | 250,000.00 |